HVTN 303

Phase I, HIV vaccine clinical trial

This study is assessing the safety, tolerability, and immune response of an adjuvanted HIV-1 fusion peptide conjugated vaccines in healthy, HIV negative adults between the ages of 18 to 50. This study is currently enrolling participants.

This trial is closed, but you can join our volunteer registry to be considered for participation in future clinical trials.